(Q39567800)

English

Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins

scientific article published on 3 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins (English)

1 reference

Europe PubMed Central

13 September 2017

7

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

13 September 2017

4

object named as

Seock-Ah Im

1 reference

Europe PubMed Central

13 September 2017

6

object named as

Do-Youn Oh

1 reference

Europe PubMed Central

13 September 2017

3

object named as

Sae-Won Han

1 reference

Europe PubMed Central

13 September 2017

5

object named as

Tae-You Kim

1 reference

Europe PubMed Central

13 September 2017

1

object named as

Kyung-Hun Lee

1 reference

Europe PubMed Central

13 September 2017

author name string

Ju-Hee Lee

2

1 reference

Europe PubMed Central

13 September 2017

publication date

3 May 2011

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

102

1 reference

Europe PubMed Central

13 September 2017

7

1 reference

Europe PubMed Central

13 September 2017

1388-1395

1 reference

Europe PubMed Central

13 September 2017

HSP90 and the chaperoning of cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

The treatment of advanced gastric cancer: current strategies and future perspectives.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Chemotherapy for metastatic gastric cancer: past, present, and future

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Heat Shock Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Biology of SNU cell lines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01944.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2011.01944.X

1 reference

Europe PubMed Central

13 September 2017

release_capz63dwlba7pmifwpbeltef6i

1 reference

https://api.fatcat.wiki/v0/release/capz63dwlba7pmifwpbeltef6i

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39567800&oldid=1855151545"